Search research articles
Contact Us
Filters
Showing results (191-200 of 325) with videos related to
Page
of 33
Sort By:
British Journal of Haematology
|
August 22, 2013
Promoter methylation patterns in Richter syndrome affect stem-cell maintenance and cell cycle regulation and differ from de novo diffuse large B-cell lymphoma
Andrea Rinaldi, Afua Adjeiwaa Mensah, Ivo Kwee, et al.
European Journal of Medicinal Chemistry
|
January 12, 2023
Investigation of morpholine isosters for the development of a potent, selective and metabolically stable mTOR kinase inhibitor
Martina De Pascale, Lukas Bissegger, Chiara Tarantelli, et al.
Leukemia & Lymphoma
|
June 12, 2010
Patterns of survival of follicular lymphomas at a single institution through three decades
Annarita Conconi, Maddalena Motta, Francesco Bertoni, et al.
Oncotarget
|
November 12, 2016
OTX015 (MK-8628), a novel BET inhibitor, exhibits antitumor activity in non-small cell and small cell lung cancer models harboring different oncogenic mutations
Maria E Riveiro, Lucile Astorgues-Xerri, Ramiro Vazquez, et al.
Oncotarget
|
December 10, 2016
The bromodomain inhibitor OTX015 (MK-8628) exerts anti-tumor activity in triple-negative breast cancer models as single agent and in combination with everolimus
Ramiro Vázquez, María E Riveiro, Lucile Astorgues-Xerri, et al.
European Journal of Haematology
|
April 23, 2010
The clinical and biological features of a series of immunophenotypic variant of B-CLL
Lilla Cro, Andrea Ferrario, Marta Lionetti, et al.
British Journal of Haematology
|
May 15, 2009
The prognosis of clinical monoclonal B cell lymphocytosis differs from prognosis of Rai 0 chronic lymphocytic leukaemia and is recapitulated by biological risk factors
Davide Rossi, Elisa Sozzi, Alessia Puma, et al.
Cancers
|
June 7, 2019
The Novel TORC1/2 Kinase Inhibitor PQR620 Has Anti-Tumor Activity in Lymphomas as a Single Agent and in Combination with Venetoclax
Chiara Tarantelli, Eugenio Gaudio, Petra Hillmann, et al.
RSC Medicinal Chemistry
|
January 22, 2021
Understanding the mechanism of action of pyrrolo[3,2-<i>b</i>]quinoxaline-derivatives as kinase inhibitors
Andrea Unzue, Claudia Jessen-Trefzer, Dimitrios Spiliotopoulos, et al.
Blood Advances
|
May 17, 2021
Study of the antilymphoma activity of pracinostat reveals different sensitivities of DLBCL cells to HDAC inhibitors
Afua Adjeiwaa Mensah, Filippo Spriano, Giulio Sartori, et al.
Page
of 33
Search research articles
Search
Showing results (191-200 of 325) with videos related to
Sort By:
Page
of 33
British Journal of Haematology
|
August 22, 2013
Promoter methylation patterns in Richter syndrome affect stem-cell maintenance and cell cycle regulation and differ from de novo diffuse large B-cell lymphoma
Andrea Rinaldi, Afua Adjeiwaa Mensah, Ivo Kwee, et al.
European Journal of Medicinal Chemistry
|
January 12, 2023
Investigation of morpholine isosters for the development of a potent, selective and metabolically stable mTOR kinase inhibitor
Martina De Pascale, Lukas Bissegger, Chiara Tarantelli, et al.
Leukemia & Lymphoma
|
June 12, 2010
Patterns of survival of follicular lymphomas at a single institution through three decades
Annarita Conconi, Maddalena Motta, Francesco Bertoni, et al.
Oncotarget
|
November 12, 2016
OTX015 (MK-8628), a novel BET inhibitor, exhibits antitumor activity in non-small cell and small cell lung cancer models harboring different oncogenic mutations
Maria E Riveiro, Lucile Astorgues-Xerri, Ramiro Vazquez, et al.
Oncotarget
|
December 10, 2016
The bromodomain inhibitor OTX015 (MK-8628) exerts anti-tumor activity in triple-negative breast cancer models as single agent and in combination with everolimus
Ramiro Vázquez, María E Riveiro, Lucile Astorgues-Xerri, et al.
European Journal of Haematology
|
April 23, 2010
The clinical and biological features of a series of immunophenotypic variant of B-CLL
Lilla Cro, Andrea Ferrario, Marta Lionetti, et al.
British Journal of Haematology
|
May 15, 2009
The prognosis of clinical monoclonal B cell lymphocytosis differs from prognosis of Rai 0 chronic lymphocytic leukaemia and is recapitulated by biological risk factors
Davide Rossi, Elisa Sozzi, Alessia Puma, et al.
Cancers
|
June 7, 2019
The Novel TORC1/2 Kinase Inhibitor PQR620 Has Anti-Tumor Activity in Lymphomas as a Single Agent and in Combination with Venetoclax
Chiara Tarantelli, Eugenio Gaudio, Petra Hillmann, et al.
RSC Medicinal Chemistry
|
January 22, 2021
Understanding the mechanism of action of pyrrolo[3,2-<i>b</i>]quinoxaline-derivatives as kinase inhibitors
Andrea Unzue, Claudia Jessen-Trefzer, Dimitrios Spiliotopoulos, et al.
Blood Advances
|
May 17, 2021
Study of the antilymphoma activity of pracinostat reveals different sensitivities of DLBCL cells to HDAC inhibitors
Afua Adjeiwaa Mensah, Filippo Spriano, Giulio Sartori, et al.
Page
of 33